TABLE 4.
SNPs with detected statistically significant differences in clinical indexes.
| Genotype | Patients | NI | MAP (%) | HR (%) | Onset time (min) | Effective dose (ug) |
|---|---|---|---|---|---|---|
| ABCG2 rs2231142 | ||||||
| GG | 55 (60) | 48.15 ± 18.00 | −8.09 ± 8.63 | −13.78 ± 8.35 | 19.02 ± 12.72 | 35.73 ± 6.90 |
| GT + TT | 37 (40) | 50.65 ± 15.45* | −10.49 ± 10.80 | −12.46 ± 8.17 | 28.22 ± 19.72* | 41.21 ± 14.61 |
| CYP2D6 rs16947 | ||||||
| GG | 65 (71) | 49.05 ± 16.42 | −8.54 ± 10.39 | −12.98 ± 8.36 | 22.58 ± 15.57 | 39.22 ± 11.76 |
| GA + AA | 27 (29) | 49.41 ± 18.59 | −10.30 ± 7.28 | −13.90 ± 8.11 | 23.04 ± 18.70 | 34.84 ± 8.09* |
| WBP2NL rs5758550 | ||||||
| AA | 75 (82) | 47.15 ± 15.82 | −8.19 ± 9.96 | −12.75 ± 8.51 | 22.28 ± 15.81 | 38.51 ± 11.17 |
| AG + GG | 17 (18) | 58.00 ± 19.51* | −12.85 ± 6.68* | −15.46 ± 6.82 | 24.65 ± 19.41 | 35.37 ± 9.86 |
| KATP rs141294036 | ||||||
| CC | 82 (89) | 49.83 ± 17.43 | −9.80 ± 9.40 | −13.70 ± 8.10 | 22.65 ± 16.62 | 37.50 ± 9.64 |
| CT + TT | 10 (11) | 43.60 ± 12.01 | −2.94 ± 9.33* | −9.57 ± 9.04 | 23.30 ± 15.76 | 41.48 ± 19.01 |
| KCNMB1 rs11739136 | ||||||
| CC | 77 (84) | 49.65 ± 17.33 | −8.61 ± 9.74 | −13.98 ± 8.11 | 23.91 ± 16.47 | 37.82 ± 10.79 |
| CT + TT | 15 (16) | 46.60 ± 15.34 | −11.34 ± 8.65 | −9.51 ± 8.22 | 16.60 ± 15.42* | 38.52 ± 12.15 |
| KCNMA1 rs16934182 | ||||||
| GG | 89 (97) | 49.37 ± 17.22 | −8.58 ± 9.36 | −13.27 ± 8.38 | 23.06 ± 16.61 | 38.23 ± 11.02 |
| GA + AA | 3 3) | 42.67 ± 2.52 | −23.07 ± 4.41* | −12.73 ± 3.56 | 12.67 ± 2.52 | 29.16 ± 1.38* |
| ABCC9 rs11046209 | ||||||
| AA | 71 (77) | 46.56 ± 14.75 | −9.75 ± 9.34 | −13.62 ± 7.81 | 21.80 ± 15.61 | 37.87 ± 10.97 |
| AT + TT | 21 (23) | 57.90 ± 21.12* | −6.69 ± 10.25 | −12.01 ± 9.73 | 25.81 ± 19.11 | 38.13 ± 11.17 |
| ADRA2A rs1800544 | ||||||
| GG | 43 (47) | 46.63 ± 13.62 | −7.90 ± 8.93 | −13.07 ± 8.08 | 19.23 ± 10.43 | 35.49 ± 7.46 |
| GC + CC | 49 (53) | 51.37 ± 19.33 | −10.06 ± 10.10 | −13.41 ± 8.49 | 25.78 ± 19.93 | 40.08 ± 12.99* |
| ADRB2 rs1042713 | ||||||
| AA | 29 (32) | 49.34 ± 17.40 | −8.24 ± 9.79 | −14.25 ± 7.80 | 18.55 ± 7.65 | 35.80 ± 8.30 |
| AG + GG | 63 (68) | 49.06 ± 16.93 | −9.43 ± 9.54 | −12.79 ± 8.48 | 24.63 ± 18.94* | 38.91 ± 11.91 |
Data are expressed as n (%) or mean ± SD.
Independent-sample two-tailed t-test or Mann–Whitney U test was utilized to analyze the differences in NI, values, percent changes of MAP or HR, onset time, and effective dose between the homozygous for the major allele and the group of heterozygous and homozygous for the minor allele.
*p < 0.05 (homozygous carriers of the major allele vs. carriers of the minor allele) was considered statistically significant.
SNP, single nucleotide polymorphism; NI, narcotrend index; MAP, mean arterial pressure; HR, heart rate; SD, standard deviation.